Cosmo (COPN) Aperçu de l'action
Cosmo Pharmaceuticals N.V. se concentre sur le développement et la commercialisation de produits pour la gastro-entérologie, la dermatologie et les technologies de la santé dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
COPN Community Fair Values
Create NarrativeSee what 154 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CHF 100
FV
21.9% sous-évalué décote intrinsèque3k
users have viewed this narrative8users have liked this narrative
0users have commented on this narrative
84users have followed this narrative
Cosmo N.V. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CHF 78.10 |
| Plus haut sur 52 semaines | CHF 129.40 |
| Plus bas sur 52 semaines | CHF 53.40 |
| Bêta | 1.48 |
| Variation sur 1 mois | -13.80% |
| Variation sur 3 mois | -33.25% |
| Variation sur 1 an | 37.99% |
| Variation sur 3 ans | 55.89% |
| Variation sur 5 ans | -10.23% |
| Évolution depuis l'introduction en bourse | 250.22% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.
Mise à jour du récit • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Mise à jour du récit • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.
Mise à jour du récit • Apr 08
COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential
Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).
Mise à jour du récit • Mar 25
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).Recent updates
Mise à jour du récit • May 16
Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months
Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.Mise à jour du récit • May 11
COPN: CHF 160 Outlook Will Rely On Successful Alopecia Regulatory Filings
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions for revenue growth, profit margins and future P/E. These changes collectively support a slightly lower fair value estimate and a modestly higher discount rate in their models.Mise à jour du récit • Apr 23
COPN: Higher CHF 160 Outlook Will Depend On Upcoming Alopecia Filing
Analysts have raised their price target on Cosmo to CHF 160 from CHF 130, citing updated assumptions on fair value, revenue growth, profit margins and future P/E that contribute to a higher overall valuation framework. Analyst Commentary While the higher CHF 160 target reflects updated valuation work, bearish analysts still flag several areas where expectations could prove demanding if underlying assumptions do not play out as planned.Mise à jour du récit • Apr 08
COPN: Recent Share Placement Will Support Improved Margins And Future Earnings Potential
Analysts have adjusted their price target on Cosmo Pharmaceuticals to CHF 140.45 from CHF 147.89, citing updated views on fair value, revenue growth, profit margins and future P/E assumptions. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares on February 3, 2026 (Key Developments).Mise à jour du récit • Mar 25
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Analysts have lifted their price target on Cosmo Pharmaceuticals from CHF 104.55 to around CHF 123.72, reflecting updated assumptions for higher revenue growth, a different profit margin profile, and a higher future P/E multiple. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares that represent 5.3% of the company's outstanding shares as of February 3, 2026 (Key Developments).Mise à jour du récit • Mar 10
COPN: Recent Share Placement Will Support Stronger Revenue And Margin Outlook
Analysts have nudged their price target on Cosmo Pharmaceuticals slightly lower to around CHF148 from approximately CHF150, reflecting updated assumptions on fair value, revenue growth and profit margins while keeping future P/E expectations broadly in line with prior views. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, which represent 5.3% of the company's outstanding shares, on February 3, 2026 (Key Developments).Mise à jour du récit • Feb 24
COPN: Recent Share Placement Will Support Bullish Long Term Outlook
Analysts have trimmed their price target on Cosmo Pharmaceuticals by CHF 0.00 to reflect slightly updated assumptions on revenue growth, profit margins and future P/E, while keeping their overall fair value view effectively unchanged. What's in the News Cosmo Pharmaceuticals completed a private placement with a single institutional investor, issuing 937,086 treasury shares, equal to 5.3% of outstanding shares, on February 3, 2026 (Key Developments).Mise à jour du récit • Feb 10
COPN: EU Acne Approval And Share Placement Will Support Bullish Outlook
Analysts now set their price target for Cosmo Pharmaceuticals closer to €150, up from about €102, citing updated assumptions for revenue growth, profit margins and future P/E, which feed into a higher fair value estimate. What's in the News Cosmo Pharmaceuticals completed a private placement of 937,086 treasury shares, representing 5.3% of its outstanding shares, with a single institutional investor on February 3, 2026.Mise à jour du récit • Jan 26
COPN: EU Acne Launch And Margin Assumptions Will Likely Keep Shares Fairly Valued
Analysts have moderately raised their price target on Cosmo Pharmaceuticals, citing updates to their fair value estimate along with revised assumptions for revenue growth, profit margins and future P/E. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream) following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Mise à jour du récit • Jan 11
COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended
Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).Mise à jour du récit • Dec 24
COPN: EU Acne Approval And Rollout Are Expected To Support Balanced Outlook
Analysts have modestly trimmed their price target for Cosmo Pharmaceuticals by approximately $0.48, reflecting refined assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for the treatment of acne vulgaris in adults and adolescents 12 to under 18 years, with adolescent use limited to facial application only Key Developments Cosmo Pharmaceuticals and Glenmark Pharmaceuticals secure EU wide approval enabling commercialization of Winlevi across 15 countries, including France, Spain, the Netherlands, and the Nordics Key Developments Glenmark prepares to launch Winlevi in a staged rollout across Bulgaria, the Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Portugal, Romania, Slovakia, Sweden, and other approved EU markets Key Developments Valuation Changes The Fair Value Estimate has fallen slightly to CHF 98.24 from CHF 98.72, reflecting a modest downward adjustment in intrinsic valuation.Mise à jour du récit • Dec 09
COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook
Analysts have nudged their price target for Cosmo Pharmaceuticals slightly higher to approximately $98.72 per share from about $98.59, citing expectations for stronger revenue growth that more than offset a modestly lower projected profit margin and valuation multiple. What's in the News European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with adolescent use restricted to facial application EU Marketing Authorization Approval follows a positive CHMP opinion issued on August 25, 2025, confirming regulatory momentum for Cosmo Pharmaceuticals dermatology portfolio EU Marketing Authorization Commercial launch of Winlevi to be led by partner Glenmark Pharmaceuticals across 15 European countries, including France, Spain, the Netherlands, and the Nordics, expanding Cosmo Pharmaceuticals geographic reach EU Marketing Authorization Valuation Changes Fair Value Estimate has risen slightly to CHF 98.72 from CHF 98.59 per share, reflecting a marginal upward revision to intrinsic value.Article d’analyse • Dec 05
Cosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 35% But Its P/E Still Looks Reasonable
The Cosmo Pharmaceuticals N.V. ( VTX:COPN ) share price has done very well over the last month, posting an excellent...Mise à jour du récit • Nov 25
COPN: EU Approval And Expanded Distribution Expected To Drive Share Performance
Analysts have raised their price target for Cosmo Pharmaceuticals from $87.81 to $98.59. They cite updated fair value assessments and recent model adjustments as the reasons for the change.Mise à jour du récit • Sep 04
Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges
Cosmo Pharmaceuticals’ consensus revenue growth forecasts have strengthened and its future P/E valuation has decreased, but despite these more favourable fundamentals, the consensus analyst price target was only marginally reduced from CHF88.37 to CHF87.81. What's in the News Issued FY2025 guidance: total revenues expected between EUR 102 million and EUR 107 million, with recurring revenues of EUR 85 million to EUR 90 million and project-based revenues of EUR 17 million.
Nouveau récit • Mar 17
Clascoterone Trials Completion And AI Expansion Will Open Future Markets
Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.Article d’analyse • Jan 23
Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
This weeks picks cover the promising product pipeline from a Cosmo Pharmaceutical, how NLBR bank could almost double its revenue and earnings, and why MINISO Group’s aggressive store expansion plans will pay off.Nouveau récit • Jan 20
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expandeArticle d’analyse • Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
When you see that almost half of the companies in the Pharmaceuticals industry in Switzerland have price-to-sales...Article d’analyse • May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
With a price-to-sales (or "P/S") ratio of 12.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...Article d’analyse • Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) recent earnings didn't contain any...Article d’analyse • Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Celebrations may be in order for Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders, with the analysts delivering a...Article d’analyse • Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Cosmo Pharmaceuticals N.V.'s ( VTX:COPN ) price-to-earnings (or "P/E") ratio of 67x might make it look like a strong...Article d’analyse • Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week, you might have seen that Cosmo Pharmaceuticals N.V. ( VTX:COPN ) released its interim result to the market...Article d’analyse • Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...Rendement pour les actionnaires
| COPN | CH Pharmaceuticals | CH Marché | |
|---|---|---|---|
| 7D | 2.6% | 2.8% | 1.7% |
| 1Y | 38.0% | 30.3% | 8.0% |
Rendement vs Industrie: COPN a dépassé le secteur Swiss Pharmaceuticals qui a rapporté 30.3 % au cours de l'année écoulée.
Rendement vs marché: COPN a dépassé le marché Swiss qui a rapporté 8 % au cours de l'année écoulée.
Volatilité des prix
| COPN volatility | |
|---|---|
| COPN Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.1% |
| 10% least volatile stocks in CH Market | 2.4% |
Cours de l'action stable: Le cours de l'action de COPN a été volatil au cours des 3 derniers mois par rapport au marché Swiss.
Volatilité au fil du temps: La volatilité hebdomadaire de COPN ( 7% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Swiss.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1997 | 325 | Giovanni Di Napoli | www.cosmohealthconfidence.com |
Cosmo Pharmaceuticals N.V. se concentre sur le développement et la commercialisation de produits pour la gastro-entérologie, la dermatologie et les technologies de la santé dans le monde entier. La société propose GI Genius, un système assisté par ordinateur qui utilise l'intelligence artificielle en temps réel pour détecter les lésions colorectales ; Winlevi, un médicament de prescription utilisé sur la peau pour traiter l'acné vulgaire ; Lialda/Mezavant/Mesavancol, un comprimé de mésalamine à prise quotidienne unique approuvé pour aider à mettre en rémission la colite ulcéreuse active, légère à modérée ; Uceris/Cortiment, une formulation de comprimé oral qui délivre le budésonide directement dans la lumière du côlon ; Eleview, une composition injectable permettant aux endoscopistes une excision plus rapide et moins risquée des lésions gastro-intestinales ; Lumeblue, un médicament diagnostique pour la visualisation des lésions colorectales pendant les coloscopies ; Aemcolo/Relafalk, un produit pharmaceutique sous forme de comprimés approuvé pour le traitement de la diarrhée du voyageur ; et Byfavo, un sédatif/anesthésique à base de benzodiazépine administré par voie intraveineuse. Elle développe également Breezula, un nouvel inhibiteur des récepteurs androgéniques, qui est en phase III d'essais et qui cible les récepteurs androgéniques dans le cuir chevelu ; Rifamycin 1% enema qui est en phase II d'essais cliniques pour le traitement de la colite ulcéreuse distale et de la proctite ; Colesevelam, qui fait l'objet d'études précliniques pour le traitement de la diarrhée due aux acides biliaires ; et Cortexolone 17a-valerate-21-propionate, un antagoniste oral des récepteurs des androgènes et des glucocorticoïdes qui fait l'objet d'un essai clinique de phase I pour le traitement des tumeurs solides, ainsi que la technologie AI de Cosmo, un système d'endoscopie intelligente GI Genius.
Cosmo N.V. Résumé des fondamentaux
| COPN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CHF 1.26b |
| Bénéfices(TTM) | -CHF 3.29m |
| Recettes(TTM) | CHF 94.89m |
13.3x
Ratio P/S-384.8x
Ratio P/ELe site COPN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| COPN compte de résultat (TTM) | |
|---|---|
| Recettes | €104.17m |
| Coût des recettes | €53.62m |
| Marge brute | €50.56m |
| Autres dépenses | €54.16m |
| Les revenus | -€3.61m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Jul 23, 2026
| Résultat par action (EPS) | -0.22 |
| Marge brute | 48.53% |
| Marge bénéficiaire nette | -3.46% |
| Ratio dettes/capitaux propres | 0.06% |
Quelles ont été les performances à long terme de COPN?
Voir les performances historiques et les comparaisonsDividendes
2.4%
Rendement actuel des dividendes-929%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 14:10 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cosmo N.V. est couverte par 11 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Estelle Bétrisey | Berenberg |
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |